Pharmacological Blockade of TGF-Beta Reduces Renal Interstitial Fibrosis in a Chronic Ischemia–Reperfusion Animal Model
Drugs and Drug Candidates · 13.03.2023 · 2 (1) · 137-147
DOI: 10.3390/ddc2010009 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drugs and Drug Candidates, online erschienen am 13.03.2023. Verfasst von Zesergio Melo und 12 weiteren Autor:innen. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CONACYT Mexico.
Abstract (Originalsprache)
The targeting of transforming growth factor β (TGF-β) has been shown to reduce complications related to ischemia-reperfusion injury (IRI) post-surgically. Pirfenidone (PFD) specifically inhibits TGF-β expression and has been demonstrated to provide protection from IRI in short-term allograft models, though not yet in long-term models. A chronic unilateral IRI model was established using male Wistar rats. The animals were divided into two groups: one with IRI and a pre-treatment of PFD (0.5 mg/kg) followed by 0.5 mg/kg/day of orally administered PFD for 30 days, and a control group without PFD treatment. A sham group was also included. Kidneys and blood samples were collected after 30 days, and the renal function was evaluated by measuring the serum creatinine and KIM-1 levels. RT-PCR was used to analyze fibrosis-related genes, and Luminex to quantify the pro-inflammatory serum IL-18 cytokine. Renal section staining and histological analysis were used to detect collagen deposits. Comparison within the groups showed an increase in serum creatinine and KIM-1 expression after IRI in the control group, while PFD reduced COLL1A1 and TGF-β expression and demonstrated a reduction in fibrosis through histological stains. The treatment group also showed a reduction in IL-18. Our results suggest that PFD exerts protective effects on chronic renal IRI, reducing fibrosis development and inflammation. This study provides new insights into the treatment and management of chronic renal function loss after IRI.
Förderung
- CONACYT Mexico
Zitieren
APA
Melo, Z., Palomino, J., Franco-Acevedo, A., García, D., González-González, R., Verdugo-Molinares, M. G., Buen, E. P., Moreno-Carranza, B., Fuentes-Orozco, C., Barbosa-Camacho, F. J., Reyes-Elizalde, E. A., Cortés-Sanabria, L., & González-Ojeda, A. (2023). Pharmacological Blockade of TGF-Beta Reduces Renal Interstitial Fibrosis in a Chronic Ischemia–Reperfusion Animal Model. Drugs and Drug Candidates, 2(1), 137-147. https://doi.org/10.3390/ddc2010009
Vancouver
Melo Z, Palomino J, Franco-Acevedo A, García D, González-González R, Verdugo-Molinares MG, et al. Pharmacological Blockade of TGF-Beta Reduces Renal Interstitial Fibrosis in a Chronic Ischemia–Reperfusion Animal Model. Drugs and Drug Candidates. 2023;2(1):137-147. doi:10.3390/ddc2010009
BibTeX
@article{Melo2023,
author = {Melo, Zesergio and Palomino, Julio and Franco-Acevedo, Adriana and García, David and González-González, Ricardo and Verdugo-Molinares, Maritza G. and Buen, Eliseo Portilla-de and Moreno-Carranza, Bibiana and Fuentes-Orozco, Clotilde and Barbosa-Camacho, Francisco J. and Reyes-Elizalde, Emilio A. and Cortés-Sanabria, Laura and González-Ojeda, Alejandro},
title = {Pharmacological Blockade of TGF-Beta Reduces Renal Interstitial Fibrosis in a Chronic Ischemia–Reperfusion Animal Model},
journal = {Drugs and Drug Candidates},
year = {2023},
volume = {2},
number = {1},
pages = {137--147},
doi = {10.3390/ddc2010009}
}
EUVIMED